Understanding how regulatory T cells affect cancer treatment
Regulatory T cells and the tumor microenvironment
This study is looking at how certain immune cells called regulatory T cells affect cancer treatment and aims to find ways to make cancer therapies work better by managing these cells, which could help improve outcomes for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10908568 on NIH RePORTER |
What this research studies
This research investigates the role of regulatory T cells in the tumor microenvironment and their impact on cancer immunotherapy. The team aims to identify mechanisms that inhibit anti-tumor immunity and develop strategies to selectively limit the activity of these cells in tumors without causing harmful autoimmune effects. By focusing on innovative approaches, the research seeks to enhance the effectiveness of existing cancer treatments and improve patient outcomes. Patients may benefit from insights gained through this research that could lead to more effective immunotherapeutic strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with various types of cancer who are undergoing or considering immunotherapy.
Not a fit: Patients with non-cancerous conditions or those not receiving immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatments that enhance the body's immune response against tumors.
How similar studies have performed: Previous research has shown promising results in targeting immune inhibitory mechanisms in cancer, indicating potential for success in this area.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Vignali, Dario Aa — University of Pittsburgh at Pittsburgh
- Study coordinator: Vignali, Dario Aa
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.